Showing results (151-160 of 257) with videos related to
Sort By:
Pageof 26
Blood|December 3, 2003
Molecular response to imatinib in late chronic-phase chronic myeloid leukemiaGianantonio Rosti, Giovanni Martinelli, Simona Bassi, et al.Cancer|May 17, 2002
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent courseSrdan Verstovsek, Hui Lin, Hagop Kantarjian, et al.British Journal of Haematology|November 16, 2011
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)Sergio Amadori, Roberto Stasi, Alberto M Martelli, et al.Hematological Oncology|September 29, 2023
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE studyPaolo Sportoletti, Luca Laurenti, Annalisa Chiarenza, et al.Haematologica|June 21, 2011
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinibMassimo Breccia, Roberto Latagliata, Fabio Stagno, et al.Journal of Clinical Medicine|February 7, 2020
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical TrialClaudio Cerchione, Giovanni Martinelli, Marco Picardi, et al.Cancer|January 3, 2014
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvementSimona Soverini, Caterina De Benedittis, Cristina Papayannidis, et al.Haematologica|August 2, 2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective studyMichele Baccarani, Daniela Cilloni, Michela Rondoni, et al.Haematologica|October 8, 2008
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upFrancesca Palandri, Fausto Castagnetti, Nicoletta Testoni, et al.Blood|August 21, 2004
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani, Giovanni Martinelli, Gianantonio Rosti, et al.Pageof 26